1	TITLE: Impact of Remote Cholecystectomy on Clinical Outcomes Following Pseudomonas
2	aeruginosa Bloodstream Infection: A Retrospective Cohort Study
3	
4	AUTHORS: Hanna K. Bertucci ^{a,*} , Lyndsey R. Heise ^{a,b,*} , Michael P. Angarone ^a , Alan R.
5	Hauser ^{a,c} , Marc H. Scheetz ^{a,d,e} , Kelly E. R. Bachta ^{a,#}
6	
7	AFFILIATIONS:
8	^a Department of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg
9	School of Medicine, Chicago, Illinois, USA
10	^b Department of Infectious Diseases and Travel Medicine, Springfield Clinic, Springfield, Illinois,
11	USA
12	^c Department of Microbiology-Immunology, Northwestern University, Feinberg School of
13	Medicine, Chicago, Illinois, USA
14	^d Departments of Pharmacy Practice and Pharmacology, Pharmacometric Center of Excellence,
15	Midwestern University, Chicago College of Pharmacy, Downers Grove, Illinois, USA
16	^e Department of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA
17	
18	*Co-first authors: Hanna K. Bertucci and Lyndsey R. Heise contributed equally to this work.
19	Author order was determined after shared discussion.
20	
21	[#] Corresponding author: Kelly Bachta, <u>kelly.bachta@northwestern.edu</u> , ORCID: 0000-0001-
22	8838-5117
23	

24 KEYWORDS

25 Pseudomonas aeruginosa, cholecystectomy, antimicrobial resistance, bloodstream infection

26

27 ABBREVIATIONS

- 28 Pseudomonas aeruginosa (Pa); Pseudomonas aeruginosa bloodstream infection (PABSI);
- 29 bloodstream infection (BSI); antimicrobial resistance (AMR); multidrug-resistant (MDR),
- 30 extensively drug-resistant (XDR); gallbladder (GB); gastrointestinal (GI)

31

33 **ABSTRACT:**

Purpose: Mortality associated with *Pseudomonas aeruginosa* bloodstream infection (PABSI) remains high despite advances in clinical care and therapeutics. In a recent study using mice to model PABSI, the gallbladder (GB) was identified as a reservoir for bacterial expansion. Furthermore, bile exposure has been linked to increased antimicrobial resistance (AMR). Therefore, we asked whether patients with retained gallbladders might suffer from more antimicrobial resistant *P. aeruginosa* (*Pa*) infections, extended culture positivity, and worsened clinical outcomes.

41

Methods: Retrospective cohort study of adults hospitalized over a five-year period with PABSI.
PABSI cases were defined as patients with ≥ 1 positive *Pa* bacterial culture from the blood.
Patients were categorized as either those retaining a gallbladder (no cholecystectomy) or those
without (cholecystectomy). Cholecystectomy was defined as a history of cholecystectomy ≥ 1
year prior to the index episode of PABSI. Inferential statistics were used to identify associations
between remote cholecystectomy and antimicrobial resistance profile, length of blood culture
positivity, and in-hospital and 90-day mortality.

49

50 **Results**: The final study population included 336 patients, 262 (78%) with retained gallbladder 51 and 74 (22%) without. We observed no difference in 90-day or in-hospital mortality between 52 groups. Overall, composite 90-day mortality was 30.1%. Furthermore, no robust differences 53 were observed in the antimicrobial resistance profile of *Pa* isolates between the groups.

54

55 Conclusions: In our study, neither PABSI AMR pattern nor clinical outcome was affected by 56 remote cholecystectomy. However, we do demonstrate that mortality for patients with PABSI in 57 the modern era remains high despite advances in anti-pseudomonal therapeutics.

58

59 **INTRODUCTION**

60 Bloodstream infections (BSIs), as defined by the ability to culture bacteria from the 61 bloodstream of a patient with signs of systemic infection, are a growing threat to public health. It 62 is estimated that over 575,000 cases of BSIs occur annually in North America leading to over 90,000 patient deaths per year [1]. Positive blood cultures in the context of infection have been 63 shown to increase overall mortality risk and BSIs are a leading cause of sepsis, an often-64 65 devastating consequence of infection. Hospitalization due to BSI lasts up to 20 days longer 66 than other admissions, leading to significant economic consequences for the patient and 67 increased resource burden on healthcare systems [2]. In patients whose BSI progresses to 68 clinical sepsis, the average length of hospitalization increases by 75% making sepsis the most 69 expensive condition to treat in the hospital [3, 4]. Sepsis is often fatal and those patients who 70 do survive are more likely to have permanent organ damage and physical and mental 71 impairments [4]. Among all bacterial organisms that cause BSIs, Gram-negative organisms are 72 increasing at an alarming rate.

73 One such organism is *Pseudomonas aeruginosa* (Pa). Pa is an opportunistic, environmental Gram-negative bacterium, that commonly causes healthcare-associated 74 infections including BSI. Pa is the 4th leading cause of BSIs, comprising approximately 4-9% of 75 76 all episodes [5, 6]. Compared to all other bacterial species, BSI secondary to Pa carries a 77 disproportionately high risk of mortality [7, 8] with reported crude mortality rates ranging widely 78 from 20 to 70% [7-11]. A 13-year prospective study that evaluated 2600 patients with BSI and 79 adjusted for antimicrobial resistance (AMR) patterns and comorbidities, found that the mortality 80 for Pa BSI (PABSI) was higher than that of all other bacterial pathogens including 81 Staphylococcus aureus [7]. PABSI is typically acquired in situ via central venous catheters, or 82 secondarily following dissemination from an invasive infection such as pneumonia or urinary 83 tract infection [11, 12]. Risk factors for PABSI include prolonged hospitalization, neutropenia, 84 liver and biliary disease, immunodeficiency, the presence of an indwelling catheter and prior

85 gastrointestinal (GI) colonization with Pa [10, 13-16]. Factors such as delayed effective antibiotic treatment, neutropenia, underlying pneumonia, and more severe disease at time of 86 87 presentation have been associated with poor PABSI outcomes [9, 17]. Additionally, rising AMR 88 rates worsen the prognosis for PABSI. Multidrug-resistance (MDR) rates for Pa are among the 89 highest of all BSI-causing pathogens, occurring in more than a guarter of all isolates [5]. Given 90 the rise in drug resistance, Pa is one of the top two pathogens frequently initially treated with 91 inappropriate antibiotic therapy [18], and inadequate or delayed onset of antibiotic therapy has been shown to worsen prognosis [17, 18]. Despite the development of newer antimicrobial 92 93 combinations to combat rising AMR (e.g. ceftazidime-avibactam and ceftolozane-tazobactam), limited headway has been made in reducing overall PABSI mortality likely related to an 94 95 incomplete understanding of pathophysiology.

96 In a recent report, Bachta, et al. used a mouse infection model to better understand 97 PABSI intra-host infection dynamics [19]. Notably, following PABSI, Pa was found to traffic to 98 the gallbladder (GB) where the population expanded dramatically and facilitated high levels of 99 excretion of Pa into the gastrointestinal (GI) tract. Remarkably, post infection, the gallbladder 100 contained the highest bacterial burden of any organ. Removal of the gallbladder led to dramatic 101 reductions in the fecal excretion of Pa, thereby suggesting that the gallbladder may be a 102 previously underappreciated niche for Pa expansion. Pa was also shown to replicate robustly in 103 bile in vitro. In human studies evaluating the causative agents of cholecystitis and cholangitis, 104 Pa is among the top five most frequently isolated pathogens [20, 21], and its presence in the 105 gallbladder has been associated with the development of secondary sclerosing cholangitis [22].

The gallbladder acts as an important reservoir for bile, a complex mixture of bile acids, phospholipids, cholesterol, bilirubin, inorganic salts and trace metals [23]. Bile is one of the most inherently bactericidal compounds in the human body, serving to decrease bacterial burden in the GI tract. Several studies have demonstrated that the gallbladder is an important replicative niche for certain bacterial species. It has been shown to facilitate persistent

111 colonization and enhance transmission of Salmonella typhi, Listeria monocytogenes and 112 Campylobacter jejuni [24-27]. Gallbladder epithelial cells serve as the niche for in vivo 113 replication of Salmonella enterica serovar Typhi [28] and L. monocytogenes replicates within the 114 lumen of the murine gallbladder [29]. As in PABSI, mouse models of BSI demonstrated that L. 115 monocytogenes also traffics to the liver and gallbladder and is subsequently excreted in the GI To promote survival and GI colonization, bacteria have developed 116 tract [26, 30, 31]. 117 mechanisms that subvert the toxic effects of bile through adaptation and tolerance [24], and 118 many utilize bile as a signal to enhance virulence gene regulation for efficient infection [24]. L. 119 monocytogenes expresses a bile salt hydrolase that, when deleted, decreases virulence [32]. 120 Exposure to bile promotes germination of *Clostridioides difficile*, an important cause of infectious 121 colitis in patients. Other mechanisms that promote bile tolerance include induction of biofilm 122 formation and intracellular invasion of gallbladder epithelial cells, a phenomenon thought to 123 promote chronic carriage and GI shedding of Salmonella [33]. Critically, bile exposure has been 124 linked to promotion of increased antimicrobial resistance. There is mounting evidence in E. coli, Enterobacter cloacae, Klebsiella pneumoniae, Acinetobacter baumannii, and Pa that bile 125 126 exposure stimulates efflux pump expression enhancing the ability of bacteria to survive in harsh 127 environments [24, 34]. For example, bile exposure in *E. coli* increases expression of multidrug-128 efflux pumps including AcrAB and EmrAB that promote bile tolerance and increase antibiotic 129 efflux [35, 36]. In S. typhimurium, an AcrB-like protein that encodes for an efflux pump 130 contributes to resistance to both bile salts and detergents [37, 38]. Bile exposure in 131 Enterococcus faecalis induces genes encoding for EmrB/QacA family drug resistance 132 transporters and increases expression of phospholipid synthetase which is linked to daptomycin 133 resistance [39]. Thus, increased exposure to bile may be contributing to rising antimicrobial 134 resistance in pathogenic bacteria. However, how these responses impact overall survival is 135 poorly understood.

136 There are limited studies investigating the responses of *Pa*, a non-enteric pathogen, to 137 bile. Pa replicates robustly in bile, and bile exposure has been shown to stimulate the 138 production of Pa virulence factors including genes important in biofilm formation, cell envelope 139 biogenesis, guorum sensing, Type VI secretion, and antimicrobial tolerance [19, 34, 40-42]. In 140 the lungs of patients with cystic fibrosis and structural lung disease, bile aspiration is associated 141 with the early acquisition of Pa [43, 44]. Once established in the lungs of such patients, Pa is 142 exceedingly difficult to eradicate as ongoing bile exposure secondary to gastroesophageal reflux 143 potentiates adaptations that allow for persistent colonization [41, 45]. Given that Pa replicates in bile, traffics to the gallbladder following BSI, and is commonly cultured from patients with 144 145 gallbladder infections, we questioned if the presence of a gallbladder played a role in PABSI 146 outcome. We hypothesized that the gallbladder might facilitate greater Pa exposure to bile and 147 promote the development of antimicrobial resistance. Additionally, we hypothesized that prior 148 cholecystectomy (gallbladder removal) through elimination of an *in vivo* replication niche, may 149 improve outcomes following PABSI. The purpose of this retrospective analysis was to evaluate 150 the impact of cholecystectomy on AMR development and infection outcomes in patients with 151 PABSI.

152 MATERIALS AND METHODS

153 Study setting, design, and protocol

In this retrospective cohort study, we examined patients with *Pa* bloodstream infections hospitalized at Northwestern Memorial Hospital (NMH) and Prentice Women's Hospital from July 1, 2014 to July 1, 2019. NMH is an 894-bed academic medical center with a full range of clinical services including a robust immunocompromised patient population. As *Pa* is rarely a contaminant in the bloodstream, patients were considered to have PABSI if \geq 1 blood culture was positive for *Pa*. The first positive isolate per patient was included in this analysis. Exclusion criteria included: patients aged less than 18 years, those who had undergone a

medRxiv preprint doi: https://doi.org/10.1101/2024.01.26.24301822; this version posted January 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

161 cholecystectomy within the last 1 year, patients with HIV/AIDS and pregnant women. Patients 162 with polymicrobial bacteremia were included in the study. This project was reviewed and 163 approved by the Northwestern University Institutional Review Board (project no. STU00210641). 164 Inpatient electronic medical records (NMH Enterprise Data Warehouse), pharmacy and microbiology databases were reviewed. Patient demographics included gender, age, and 165 166 number of days from admission to the first positive blood culture. The presence of the following 167 comorbid conditions was documented: neutropenia, localized solid tumor, metastatic solid 168 tumor, leukemia/lymphoma, myocardial infarction, concestive heart failure, peripheral vascular 169 disease, COPD, chronic kidney disease, diabetes mellitus, CVA/TIA, dementia, hemiplegia, 170 peptic ulcer disease, liver disease, and connective tissue disease. Charlson comorbidity index 171 (CCI) was calculated at the time of bacteremia to estimate illness severity [46]. Charts were 172 reviewed for evidence of cholecystectomy (gallbladder removal) through identification via ICD-9 173 or ICD-10 code or through absence of a gallbladder on abdominal computed tomography (CT) 174 scan. For patients with a history of cholecystectomy, the approximate procedure date and 175 reason were recorded, if available. Recorded characteristics of BSIs included the suspected 176 source of infection, whether the infection was polymicrobial, and whether the infection was 177 hospital-acquired (nosocomial, onset \geq 72 hours after admission). The following aspects of antimicrobial therapy were recorded: time to active therapy, length of blood culture positivity, 178 179 and culture susceptibility to antibiotics spanning seven classes as detailed below. Length of 180 culture positivity was determined by manual chart review. Outcomes included length of blood 181 culture positivity, 90-day and in-hospital mortality if < 90 days.

182

183 Microbiology

Blood cultures from hospitalized patients were processed by the NMH Microbiology Laboratory using the BacT/ALERT® blood culture system (bioMérieux, Marcy l'Etoile, France), with each set consisting of aerobic and anaerobic cultures. Genus and species identification of bacteria

187 was performed via mass spectrometry identification using MALDI-TOF (bioMérieux) or manual 188 biochemical assays when necessary. Susceptibility testing was performed by either the Vitek II 189 system to determine minimal inhibitory concentration (MIC) or Kirby Bauer disk diffusion on 190 Mueller-Hinton agar plates. Antimicrobial agents tested included ciprofloxacin, cefepime, 191 ceftazidime. piperacillin/tazobactam, ceftazidime/avibactam, ceftolozane/tazobactam, 192 meropenem, imipenem, aztreonam, amikacin, gentamicin, tobramycin, colistin, polymyxin B, 193 and tigecycline. MICs and zones of inhibition were categorically interpreted according to Clinical and Laboratory Standards Institute (CLSI, 30th edition) guidelines [47]. 194

195

196 **Definitions**

Neutropenia was defined as an absolute neutrophil count < 500/mm³ [48]. Nosocomial 197 198 bacteremia was defined as bacteremia acquired ≥ 72 hours after hospitalization. Polymicrobial 199 bloodstream infection was defined as concurrent isolation of Pa plus any additional bacterium 200 from the bloodstream at time of the diagnostic blood culture. Active antimicrobial therapy was 201 defined as therapy with at least one agent to which the causative Pa strain was susceptible. 202 Specific doses were not reviewed, but all antibiotics were dosed prospectively by clinical 203 pharmacists to optimize efficacy while minimizing safety concerns. Recurrent PABSI was defined as re-isolation of *Pa* from a patient's bloodstream \geq 2 weeks from the incident episode 204 205 provided interval clearance (documented negative blood culture) of the bloodstream between Infections were categorized as multidrug resistant (MDR) if they were non-206 episodes. 207 susceptible (either intermediate or resistant) to \geq 1 agent from \geq 3 classes of antibiotics, extensively drug-resistant (XDR) if they were susceptible to ≤ 2 classes of antibiotics, and pan-208 209 drug resistant (PDR) if non-susceptible to all antibiotics tested following standardized criteria 210 [49]. Culture positivity was analyzed in two ways. First, we recorded the total number of daily 211 positive blood cultures documented regardless of follow up clearance (n=336, all patients). For 212 patients with no blood culture follow-up within 48 hours of index culture, the length of culture

positivity was recorded as 1 day. Second, we analyzed only those patients for whom there was
documented follow-up of blood cultures within 48 hours of the index positive culture (n = 220).
For patients with recurrent PABSI episodes, the longest consecutive duration of documented
positive cultures was included.

217

218 Statistical analysis

219 Statistical analyses were performed using Stata v.17.0 (Statacorp, College Station, Texas). 220 Tables were created with program table1 mc. Results were expressed as mean ± standard deviation (SD). Pearson's chi-squared test was employed for categorical variables and ANOVA 221 222 for continuous variables (with appropriate degrees of freedom between groups) to calculate p-223 values. Tests were two-tailed, and a p-value of ≤ 0.05 was used for statistical significance. 224 Length of culture positivity data lacked a parametric distribution, and thus p-values were 225 calculated using the two-sample Wilcon rank-sum (Mann-Whitney) test. Time to event analyses 226 were completed with log rank tests for assessments of equality. Kaplan-Meier curves were 227 generated using GraphPad Prism v9.0.0 (GraphPad Software, San Diego, California, USA).

228 **RESULTS**

229 Patient characteristics

230 During the study period, 352 episodes of Pa bloodstream infection were recorded in 336 unique 231 patients (Table 1) of which twelve patients (3.6%) had recurrent PABSI. The mean age of 232 patients in the study was 66.9 years and 64.3% were male. Nosocomial infections represented 233 20.8% of all infections and 17.3% of the bacteremia episodes were polymicrobial. Of the 234 individual patients evaluated, 262 (78.0%) had a gallbladder at the time of infection (no 235 cholecystectomy) and 74 (22.0%) had had prior gallbladder removal (cholecystectomy), yielding 236 a ratio of approximately 3:1 of patients with and without a gallbladder at the time of their PABSI. 237 Unsurprisingly given the predilection of females for gallbladder disease, fewer male patients had

prior cholecystectomy (43.2% vs. 70.2%, respectively; P < 0.001). The majority of patients 238 239 (64.6%) had a Charlson comorbidity Index (CCI) \geq 5 at the time of their PABSI diagnosis, and the average CCI was 6.4 in patients without a gallbladder and 5.6 in the cohort with a 240 241 gallbladder (P = 0.026). Generally, the presence of most medical comorbidities was not 242 statistically different between cohorts. However, among patients without a gallbladder, a larger 243 percentage had peripheral vascular disease (20.3% vs. 9.2%, respectively; P = 0.008) and liver 244 disease (16.2% vs. 5.0%, respectively; P = 0.001). A smaller percentage of patients without a 245 gallbladder were neutropenic (8.1% vs. 22.1%, respectively; P = 0.007) or had leukemia or 246 lymphoma (13.5% vs. 25.6%, respectively; P = 0.029). The mean time to active therapy was statistically different between the two groups (1.4 days for patients without a gallbladder vs. 0.6 247 248 days for patients with a gallbladder; P = 0.003).

249

250 Antimicrobial resistance profiles of PABSI isolates

251 To discern if prior cholecystectomy was associated with the AMR patterns of our PABSI 252 isolates, we examined the resistance profiles of each isolate. Of the 336 unique episodes of 253 PABSI, we had antimicrobial resistance data for all but 13 (3.9%) which were excluded from this 254 analysis (Table 2). As mentioned, 12 patients (3.6%) had recurrent PABSI during this study 255 period. For patients with recurrence, antibiotic susceptibility data was assessed for each 256 patient's first positive blood culture yielding a total of 323 unique isolates. Overall, for those 257 antibiotics for which we had complete data (ciprofloxacin, cefepime, ceftazidime, piperacillin-258 tazobactam, gentamicin and tobramycin), we saw the highest rates of non-susceptibility to 259 ciprofloxacin (48/323, 14.9%) followed closely by piperacillin-tazobactam (39/323, 12.1%). The 260 percentage of non-susceptible isolates for each of the above antibiotics was generally similar 261 among patients with and without a gallbladder. A greater proportion of isolates in patients without a gallbladder were non-susceptible to piperacillin/tazobactam (17.1% vs 10.7%, P =262 0.14), gentamicin (12.9% vs. 7.9%, P = 0.20), and colistin (41.7% vs. 30.6%, P = 0.48), though 263

264 none of these results achieved statistical significance. Of the 323 isolates, we had meropenem susceptibility data for 282, of which 8.2% were non-susceptible. Very few isolates underwent 265 266 testing for ceftazidime/avibactam or ceftolozane/tazobactam as the study period was prior to 267 extensive clinical use of these antimicrobial agents. A relatively large percentage of PABSI 268 episodes were characterized as MDR (12.1%) or XDR (4.3%), but there was no statistical 269 difference in MDR or XDR phenotype observed between patients without or with a gallbladder 270 (MDR 12.9% vs. 11.9%, P = 0.82; XDR 2.9% vs. 4.8%, P = 0.49, respectively). No isolates 271 were pan-drug resistant. Overall, across all seven classes of antibiotics, we did not observe 272 statistically significant differences in AMR patterns that were correlated with the presence of a gallbladder at the time of PABSI diagnosis. 273

274

275 The impact of prior cholecystectomy on outcome of PABSI

We examined several outcomes measures in our patient population. There was a statistically significant difference in the time to active therapy in the two study populations (1.4 days for the cohort without a gallbladder vs. 0.6 for the cohort with a gallbladder, P = 0.003) (Table 1).

279 No significant difference in duration of bacteremia was observed between the two populations 280 when analyzing all included patients (n = 336). Average length of culture positivity for the entire cohort was 1.2 days, with averages of 1.5 days for the group lacking a gallbladder and 1.2 days 281 282 for the group who retained a gallbladder (P = 0.19) (Table 3). We also analyzed a subset of patients for whom we had documented follow up blood cultures within 48 hours of their index 283 284 positive culture (n = 220). This subset excluded patients who died prior to repeat blood cultures 285 being drawn. Notably, the majority of patients in both populations (cholecystectomy n = 50, no 286 cholecystectomy n = 170) cleared their cultures within 48 hours. Again, no significant difference 287 in culture positivity was observed between cohorts $(1.38 \pm 1.2 \text{ days vs } 1.17 \pm 0.6 \text{ days},$ 288 respectively; P = 0.44). Ninety-day mortality among both patient cohorts was similar (32.4%) 289 and 29.4%; P = 0.61), with a considerable number of those patients expiring in the hospital in

both cohorts (23% vs. 20.2%; P = 0.61) (Table 3). Overall, no statistically significant difference was seen between cohorts for 90-day mortality or in-hospital mortality as seen in Kaplan-Maier curves displaying mortality data (P > 0.5) (Fig. 1).

293

294 **DISCUSSION**

295 In this single-institution retrospective cohort study, we assessed the impact of prior 296 gallbladder removal on clinical outcomes and Pa antimicrobial resistance profile following 297 PABSI. No previous studies have investigated the relationship between remote cholecystectomy, development of AMR and PABSI outcomes. Several studies, however, have 298 299 investigated the impact of cholecystectomy on C. difficile incident infection (CDI), recurrence 300 and mortality [50, 51]. Given that cholecystectomy is associated with increased levels of fecal 301 secondary bile acids which confer resistance to C. difficile infection in animal models, the 302 authors proposed that cholecystectomy might protect against CDI. Patients without a 303 gallbladder did not experience higher rates of incident CDI or recurrence. However, there was a 304 significant increase in mortality in patients following cholecystectomy [51]. The reason for the 305 increase in mortality is poorly understood. Conversely, in our study investigating PABSI, having 306 a prior remote cholecystectomy did not impact clinical outcome as patients with and without a 307 gallbladder had similar durations of bacteremia, in-hospital and 90-day mortality rates. There 308 were baseline differences in the two study populations that may have masked outcome 309 differences. Neutropenia, a known risk factor for poor outcomes in PABSI, and 310 leukemia/lymphoma were more common in patients with a gallbladder, whereas peripheral 311 vascular disease and liver disease (other characteristics associated with poor PABSI outcomes) 312 were more common in patients without one. Furthermore, patients without a gallbladder 313 experienced a longer delay in the onset of active antimicrobial therapy and averaged higher CCI 314 scores at time of PABSI diagnosis. These differences may have offset and contributed to similar

315 outcomes seen in both patient populations. Overall, given these confounders, it is difficult to 316 determine the impact of baseline population differences on outcomes in our study.

317 Additionally, we found no association between prior cholecystectomy and increased 318 antibiotic resistance among PABSI isolates as there were no statistically significant differences 319 in AMR patterns dependent on the presence or absence of a gallbladder at the time of 320 diagnosis. We had theorized that in patients with an intact gallbladder during PABSI, the Pa 321 isolate may have increased bile exposure, a risk factor for the development of AMR [41]. Other 322 pathogens such as E. coli, Klebsiella pneumoniae, and enterococci have displayed unexpected resistance traits when cultured from the gallbladder, and bile exposure has been shown to 323 324 increase expression of efflux pumps critical for the development of antibacterial resistance [20, 325 34, 52, 53]. Thus, the lack of increased AMR in patients with a retained gallbladder was 326 surprising. However, several factors may explain this observation. First, the quantity of bile 327 exposure in patients following cholecystectomy is difficult to ascertain. Even in the absence of a 328 gallbladder the liver produces bile which is subsequently excreted into the small intestine. 329 Furthermore, patients who have undergone prior cholecystectomy have had at least one contact 330 with the healthcare system, thereby increasing their exposure to healthcare-associated 331 pathogens which routinely display higher patterns of antimicrobial resistance [54-57]. Finally, it is likely that in a percentage of our cohort, PABSI arose from sites other than the GI tract (e.g. 332 333 from the lungs or exogenous via indwelling catheters). In these cases, it is unlikely that Pa would have been exposed to bile in either the gallbladder or GI tract prior to infection. These 334 335 factors may have obscured any differences in AMR related to the presence or absence of a 336 gallbladder.

This study was able to place PABSIs at our institution in historical context as a similar study, completed more than a decade earlier, assessed morbidity associated with PABSI. In that study, the average patient was 57 years old, the in-hospital mortality rate was 37% [9] and one-third of all infections were polymicrobial. By comparison, our cohort was older (average

341 age 66.9 years), the in-hospital mortality was lower (20.8%), and only 17.3% of all bloodstream 342 infections were polymicrobial. We are encouraged by the 16% decline in the in-hospital 343 mortality rate of PABSI over the last 15 years and believe that there are several factors that 344 have contributed to this decline. First, we believe that recognition of rising rates of AMR, 345 particularly in Pa infections, has led to more rapid and aggressive initiation of anti-pseudomonal 346 antibiotics early in the hospital stay in those patients with risk factors for Pa infections. 347 Additionally, during the study period, newer combination antimicrobials for Pa infections including ceftazidime-avibactam and ceftolozane-tazobactam were introduced (2014 and 2015. 348 349 respectively). Both have expanded the antibiotic toolkit available to treat MDR and XDR Pa 350 infections. Lastly, there are differences in study populations between the two studies. Though 351 our cohort was considerably older than the original study, there was a dramatic reduction in the 352 rate of polymicrobial bloodstream infections. These factors may offset one another; however, 353 our study is not powered to fully assess the impact of these differences on outcomes. Despite 354 the 15-year interval between the two studies, it is important to acknowledge that the overall 355 mortality rate of PABSI remains high.

General estimates suggest that the lifetime prevalence of cholecystectomy is approximately 4.0% overall, 5.3% among women and 2.4% among men [58]. In our cohort, 22.0% of our patients with PABSI had prior cholecystectomy. Contrary to our hypothesis that cholecystectomy may confer protection against PABSI, the disproportionate number of patients without a gallbladder suggests that this population may, in fact, be vulnerable to PABSI or have significant risk factors that predispose them to PABSI.

This study has several important limitations. First, the population size was relatively small and included patients at a single center, and generalizability to larger populations and different clinical settings may be limited. Additionally, the data collected reflected a disproportionate ratio (three to one) of patients with and without a gallbladder with overall rates of cholecystectomy that were five times higher than expected based on general estimates. A

367 more balanced population and a matched cohort approach may serve to better highlight subtle 368 differences. Secondly, this analysis was limited to the first episode of PABSI observed in each 369 patient. As prior infection predisposes patients to Pa colonization and increases the risk of 370 invasive infection, there may have been colonized individuals in the cohort who were more 371 predisposed to invasive infection [15, 59]. This study did not assess whether cholecystectomy impacts Pa carriage in the gastrointestinal tract, an important risk factor for invasive disease. 372 373 Bachta, et al. demonstrated that the gallbladder is crucial for fecal excretion of Pa in mice [19]; 374 However, its role in amplification of fecal shedding in humans is unknown. Additionally, most 375 patients received prompt active antimicrobial therapy within one day of their first positive blood culture (mean days to active therapy 0.73 ± 2.1 days), limiting our ability to assess associations 376 377 between onset of appropriate antimicrobial therapy, underlying resistance patterns and 378 outcomes.

379 While we did not observe an improvement in PABSI outcomes in patients lacking a 380 gallbladder, we were able to observe improved overall survival rates following PABSIs compared to a prior study at our institution. This suggests that recognition and treatment of 381 382 PABSI may be improving, but there is still much to learn about carriage, colonization and 383 excretion of Pa. Given the observation that the gallbladder promoted increased gastrointestinal 384 excretion of *Pa* in mice, it would be interesting to investigate this question in human patients. A 385 future prospective study comparing fecal carriage of Pa in patients with and without a gallbladder following PABSI would help elucidate whether the gallbladder is important for 386 387 amplification of Pa in patients. If the presence of a gallbladder provided an important in vivo 388 replication niche and increased excretion of Pa this may change the way clinicians approach 389 patients with disseminated Pa infections. Such patients might benefit from increased infection 390 control measures that limit environmental contamination of their rooms. Additionally, 391 prophylactic elective cholecystectomy in patients with recurrent BSI or a lower threshold for emergent cholecystectomy in critically ill patients could be entertained. Ultimately, it is critical 392

393	that we continue to explore the interplay between the gallbladder, bile exposure and
394	antimicrobial resistance in the context of PABSI to better understand the pathophysiology of
395	BSIs and to enhance our ability to develop new therapeutics in light of rising rates of
396	antimicrobial resistance.

397

399 **TABLES**

400 **Table 1:** Demographic and clinical characteristics of the study population.

Baseline characteristics	All n = 336	Cholecystectomy n = 74	No cholecystectomy n = 262	P-value	
	n (%)	n (%)	n (%)	-	
Male	216 (64.3)	32 (43.2)	184 (70.2)	<0.001	
Age, y, mean (SD)	66.9 (16.3)	68.3 (18.2)	66.5 (15.7)	0.39	
Nosocomial infection ^a	70 (20.8)	18 (24.3)	52 (19.8)	0.40	
Polymicrobial infection	58 (17.3)	17 (23.0)	41 (15.6)	0.14	
Charlson comorbidity index ^b , mean					
(SD)	5.7 (2.8)	6.4 (3.0)	5.6 (2.7)	0.026	
1-2 points	32 (9.5)	5 (6.8)	27 (10.3)		
3-4 points	79 (23.5)	12 (16.2)	67 (25.6)		
≥5 points	217 (64.6)	54 (73.0)	163 (62.2)		
Days to active therapy, mean (SD)	0.73 (2.1)	1.40 (3.5)	0.55 (1.4)	0.003	
Medical comorbidity					
Neutropenic (ANC <500/mm ³)	64 (19.0)	6 (8.1)	58 (22.1)	0.007	
Localized solid tumor	50 (14.9)	10 (13.5)	40 (15.3)	0.71	
Metastatic solid tumor	48 (14.3)	13 (17.6)	35 (13.4)	0.36	
Leukemia/lymphoma	77 (22.9)	10 (13.5)	67 (25.6)	0.029	
Myocardial infarction	58 (17.3)	13 (17.6)	45 (17.2)	0.94	
Congestive heart failure	87 (25.9)	23 (31.1)	64 (24.4)	0.25	
Peripheral vascular disease	39 (11.6)	15 (20.3)	24 (9.2)	0.008	
COPD	47 (14.0)	14 (18.9)	33 (12.6)	0.17	
Chronic kidney disease	44 (13.1)	7 (9.5)	37 (14.1)	0.29	
Diabetes mellitus	94 (28.0)	24 (32.4)	70 (26.7)	0.33	
CVA/TIA	52 (15.5)	13 (17.6)	39 (14.9)	0.57	
Dementia	19 (5.7)	5 (6.8)	14 (5.3)	0.64	
Hemiplegia	13 (3.9)	2 (2.7)	11 (4.2)	0.56	
Peptic ulcer disease	10 (3.0)	1 (1.4)	9 (3.4)	0.35	
Liver disease	25 (7.4)	12 (16.2)	13 (5.0)	0.001	
Connective tissue disease	16 (4.8)	4 (5.4)	12 (4.6)	0.77	

^aNosocomial infection was defined as culture positivity after ≥72 hours of hospital stay.

^bThe Charlson comorbidity index (CCI) was computed on the day of the first positive blood culture.

	Non-susceptible ^a isolates, <i>n</i> /N (%)			
Antibiotic	All n = 323 ^b	Cholecystectomy $n = 70^{b}$	No cholecystectomy n = 253 ^b	P-value
Fluoroquinolones	-		-	·
Ciprofloxacin	48/323 (14.9)	10/70 (14.3)	38/253 (15.0)	0.88
Cephalosporins				
Cefepime	34/323 (10.5)	8/70 (11.4)	26/253 (10.3)	0.78
Ceftazidime	27/323 (8.4)	6/70 (8.6)	21/253 (8.3)	0.94
B-lactam/B-lactamase inhibitor				
Piperacillin/Tazobactam	39/323 (12.1)	12/70 (17.1)	27/253 (10.7)	0.14
Ceftazidime/Avibactam	0/2 (0.0)	0/0 (n/a)	0/2 (0.0)	n/a
Ceftolozane/Tazobactam	0/2 (0.0)	0/0 (n/a)	0/2 (0.0)	n/a
Carbapenems				
Meropenem	23/282 (8.2)	4/60 (6.7)	19/222 (8.6)	0.63
Imipenem	7/40 (17.5)	1/9 (11.1)	6/31 (19.4)	0.57
Monobactam				
Aztreonam	90/322 (28.0)	19/70 (27.1)	71/252 (28.2)	0.86
Aminoglycosides				
Amikacin	5/206 (2.4)	0/43 (0.0)	5/163 (3.1)	0.24
Gentamicin	29/323 (9.0)	9/70 (12.9)	20/253 (7.9)	0.20
Tobramycin	16/323 (5.0)	4/70 (5.7)	12/253 (4.7)	0.74
Polymyxins				
Colistin	16/48 (33.3)	5/12 (41.7)	11/36 (30.6)	0.48
Polymyxin B	2/7 (28.6)	0/0 (n/a)	2/7 (28.6)	n/a
Tigecycline	46/47 (97.9)	16/17 (94.1)	30/30 (100)	0.18
MDR ^c	39/323 (12.1)	9/70 (12.9)	30/252 (11.9)	0.82
XDR ^c	14/323 (4.3)	2/70 (2.9)	12/252 (4.8)	0.49

402 **Table 2:** Antibiotic susceptibility patterns in patients with and without prior cholecystectomy

^aStrains were designated as susceptible, intermediate, or resistant following the CLSI guidelines (M100 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition). All intermediate or resistant strains were categorized as non-susceptible and are included in this table.

^bThere were 336 unique patients, some with multiple positive cultures. For those patients (n = 12), only the resistance profile of the first episode was included. Thirteen episodes were missing ABX resistance data and were excluded from this table. This included 4 episodes from patients who had undergone a cholecystectomy and 9 who had not.


^cMultidrug-resistance (MDR) was defined as isolates non-susceptible to ≥1 agent from ≥3 classes of antibiotics and extensively drug-resistance (XDR) was defined as isolates susceptible to ≤2 classes of antibiotics tested

403

Table 3: Outcomes in patients with and without prior cholecystectomy

Patient outcomes	All n = 336	Cholecystectomy n = 74	No cholecystectomy n = 262 n (%)	P-value
	n (%)	n (%)		
Length of culture				
positivity, mean (SD) ^a	1.24 (0.8)	1.46 (1.3)	1.18 (0.6)	0.19
90-day mortality	101 (30.1)	24 (32.4)	77 (29.4)	0.61
In-hospital mortality	70 (20.8)	17 (23.0)	53 (20.2)	0.61

^aFor patients with recurrent episodes, the longest duration of positive cultures was recorded. 407



gallbladder removal (cholecystectomy, gray) or retained gallbladder (black). Results are
displayed as a function of 90-day mortality (**A**) and in-hospital mortality (**B**). P-value are >0.5 for
both graphs. Day 0 is the day of first positive blood culture

416 STATEMENTS AND DECLARATIONS

417 Ethics approval and consent to participate

- This research study (STU00210641) was reviewed by the Northwestern University Institutional
- 419 Review Board and was deemed an observational study where no ethical approval was required.
- 420

421 Competing interests

- H.K.B., L.R.H., M.P.A., A.R.H., M.S., and K.E.R.B declare that they have no relevant competing
 interests.
- 424

425 Funding

This work was supported by grants from an American Cancer Society (ACS) Clinician Scientist Development Grant (#134251-CSDG-20-053-01-MPC, awarded to K.E.R.B.), and a Pilot Award from the Northwestern Enterprise Data Warehouse (awarded to L.R.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

431

432 Authors' contributions

- The authors confirm contribution to the paper as follows: study conception and design: L.R.H.,
- 434 M.P.A., A.R.H., and K.E.R.B; data collection: H.K.B., L.R.H., and K.E.R.B.; analysis and
- 435 interpretation of results: H.K.B., M.S., L.R.H., and K.E.R.B; draft manuscript preparation: H.K.B.,
- 436 M.S., and K.E.R.B. All authors reviewed the results and approved the final version of the

437 manuscript.

439 **REFERENCES**

440 Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial 1. bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013 Jun;19(6):501-9. 441 442 PubMed PMID: 23473333. Epub 20130308. 443 Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, et al. Cost 2. 444 Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial 445 Sensitivity in a University Hospital in Barcelona. PLoS One. 2016;11(4):e0153076. PubMed 446 PMID: 27055117. Pubmed Central PMCID: PMC4824502. Epub 20160407. 447 Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions 3. 448 by Payer, 2013. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville 449 (MD)2006. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A. Inpatient care for septicemia or 450 4. sepsis: a challenge for patients and hospitals. NCHS Data Brief. 2011 Jun(62):1-8. PubMed 451 452 PMID: 22142805. 453 Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The 5. 454 Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial 455 Surveillance Program. Antimicrob Agents Chemother. 2019 Jul:63(7). PubMed PMID: 31010862. Pubmed Central PMCID: PMC6591610. Epub 20190624. 456 457 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial 6. 458 bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide 459 surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309-17. PubMed PMID: 15306996. Epub 460 20040715. Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, Jr., van Duin D. Results from 461 7. 462 a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream 463 Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob Agents Chemother. 2017 Jun;61(6). PubMed PMID: 28373189. Pubmed Central PMCID: 464 465 PMC5444115. Epub 20170524. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB. Variations in organism-466 8. specific severe sepsis mortality in the United States: 1999-2008. Crit Care Med. 2015 467 468 Jan:43(1):65-77. PubMed PMID: 25230374. 469 Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, et al. 9. 470 Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol 471 Infect Dis. 2009 Jul;64(3):311-9. PubMed PMID: 19345039. Pubmed Central PMCID: 472 PMC2693471. Epub 20090402. 473 10. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of 474 Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003 Oct;52(4):668-74. PubMed PMID: 12951354. Epub 20030901. 475 476 11. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas 477 aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998 478 Oct;17(10):701-8. PubMed PMID: 9865983. 479 12. Holmes CL, Anderson MT, Mobley HLT, Bachman MA. Pathogenesis of Gram-Negative 480 Bacteremia. Clin Microbiol Rev. 2021 Jun 16;34(2). PubMed PMID: 33692149. Pubmed Central 481 PMCID: PMC8549824. Epub 20210310. 482 13. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and 483 Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. 484 Clin Infect Dis. 2017 Nov 13;65(11):1884-96. PubMed PMID: 29020286. 485 Gomez-Zorrilla S, Camoez M, Tubau F, Canizares R, Periche E, Dominguez MA, et al. 486 14. 487 Prospective observational study of prior rectal colonization status as a predictor for subsequent 488 development of *Pseudomonas aeruginosa* clinical infections. Antimicrob Agents Chemother.

2015 Sep;59(9):5213-9. PubMed PMID: 26077248. Pubmed Central PMCID: PMC4538513.
Epub 20150615.

Hoang S, Georget A, Asselineau J, Venier AG, Leroyer C, Rogues AM, et al. Risk
factors for colonization and infection by *Pseudomonas aeruginosa* in patients hospitalized in
intensive care units in France. PLoS One. 2018;13(3):e0193300. PubMed PMID: 29522559.
Pubmed Central PMCID: PMC5844558. Epub 20180309.

Bang JH, Jung Y, Cheon S, Kim CJ, Song KH, Choe PG, et al. *Pseudomonas aeruginosa* bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by
Enterobacteriaceae. BMC Infect Dis. 2013 Jul 19;13:332. PubMed PMID: 23870005. Pubmed
Central PMCID: PMC3720192. Epub 20130719.

- 499 17. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. *Pseudomonas aeruginosa*bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial
 therapy on clinical outcome. Clin Infect Dis. 2003 Sep 15;37(6):745-51. PubMed PMID:
 502 12955633. Epub 20030823.
- Sung YK, Lee JK, Lee KH, Lee KT, Kang CI. The clinical epidemiology and outcomes of
 bacteremic biliary tract infections caused by antimicrobial-resistant pathogens. Am J
- 505 Gastroenterol. 2012 Mar;107(3):473-83. PubMed PMID: 22334249. Epub 20120214.
- 19. Bachta KER, Allen JP, Cheung BH, Chiu CH, Hauser AR. Systemic infection facilitates transmission of *Pseudomonas aeruginosa* in mice. Nat Commun. 2020 Jan 28;11(1):543.
- 508 PubMed PMID: 31992714. Pubmed Central PMCID: PMC6987207. Epub 20200128.
- Maseda E, Maggi G, Gomez-Gil R, Ruiz G, Madero R, Garcia-Perea A, et al. Prevalence
 of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance
 traits. J Clin Microbiol. 2013 Feb;51(2):518-21. PubMed PMID: 23196362. Pubmed Central
 PMCID: PMC3553897. Epub 20121128.
- 513 21. Malorni W, Paradisi S, Dupuis ML, Fiorentini C, Ramoni C. Enhancement of cell-514 mediated cytotoxicity by *Clostridium difficile* toxin A: an in vitro study. Toxicon. 1991;29(4-5):417-28. PubMed PMID: 1907410.
- Voigtlander T, Leuchs E, Vonberg RP, Solbach P, Manns MP, Suerbaum S, et al.
 Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing
 cholangitis. J Infect. 2015 May;70(5):483-90. PubMed PMID: 25659761. Epub 20150207.
- 519 23. Reshetnyak VI. Physiological and molecular biochemical mechanisms of bile formation.
- World J Gastroenterol. 2013 Nov 14;19(42):7341-60. PubMed PMID: 24259965. Pubmed
 Central PMCID: PMC3831216.
- 522 24. Sistrunk JR, Nickerson KP, Chanin RB, Rasko DA, Faherty CS. Survival of the Fittest:
 523 How Bacterial Pathogens Utilize Bile To Enhance Infection. Clin Microbiol Rev. 2016
- 524 Oct;29(4):819-36. PubMed PMID: 27464994. Pubmed Central PMCID: PMC5010752.
- 525 25. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall
- 526 bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol. 2011
- 527 Jan;9(1):9-14. PubMed PMID: 21113180. Pubmed Central PMCID: PMC3255095. Epub 528 20101129.
- 229 26. Zhang T, Abel S, Abel Zur Wiesch P, Sasabe J, Davis BM, Higgins DE, et al.
- 530 Deciphering the landscape of host barriers to *Listeria monocytogenes* infection. Proc Natl Acad
- 531 Sci U S A. 2017 Jun 13;114(24):6334-9. PubMed PMID: 28559314. Pubmed Central PMCID: 532 PMC5474794. Epub 20170530.
- 533 27. Gahan CG, Hill C. Listeria monocytogenes: survival and adaptation in the
- gastrointestinal tract. Front Cell Infect Microbiol. 2014;4:9. PubMed PMID: 24551601. Pubmed
 Central PMCID: PMC3913888. Epub 20140205.
- 536 28. Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, et al. Salmonella
- 537 infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute
- 538 typhoid fever. J Infect Dis. 2009 Dec 1;200(11):1703-13. PubMed PMID: 19852670.

29. 539 Hardy J, Francis KP, DeBoer M, Chu P, Gibbs K, Contag CH. Extracellular replication of 540 Listeria monocytogenes in the murine gall bladder. Science. 2004 Feb 6;303(5659):851-3. 541 PubMed PMID: 14764883. 542 Briones V, Blanco MM, Marco A, Prats N, Fernandez-Garayzabal JF, Suarez G, et al. 30. 543 Biliary excretion as possible origin of *Listeria monocytogenes* in fecal carriers. Am J Vet Res. 544 1992 Feb;53(2):191-3. PubMed PMID: 1575382. 545 31. Hardy J, Margolis JJ, Contag CH. Induced biliary excretion of *Listeria monocytogenes*. 546 Infect Immun. 2006 Mar;74(3):1819-27. PubMed PMID: 16495556. Pubmed Central PMCID: 547 PMC1418634. 548 Dussurget O, Cabanes D, Dehoux P, Lecuit M, Buchrieser C, Glaser P, et al. Listeria 32. 549 monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal 550 and hepatic phases of listeriosis. Mol Microbiol. 2002 Aug;45(4):1095-106. PubMed PMID: 551 12180927. 552 Gonzalez-Escobedo G, Gunn JS. Gallbladder epithelium as a niche for chronic 33. 553 Salmonella carriage. Infect Immun. 2013 Aug;81(8):2920-30. PubMed PMID: 23732169. 554 Pubmed Central PMCID: PMC3719562. Epub 20130603. 555 34. Gipson KS, Nickerson KP, Drenkard E, Llanos-Chea A, Dogiparthi SK, Lanter BB, et al. 556 The Great ESKAPE: Exploring the Crossroads of Bile and Antibiotic Resistance in Bacterial 557 Pathogens. Infect Immun. 2020 Sep 18;88(10). PubMed PMID: 32661122. Pubmed Central 558 PMCID: PMC7504946. Epub 20200918. 559 35. Nikaido H, Zgurskava HI. AcrAB and related multidrug efflux pumps of Escherichia coli. J Mol Microbiol Biotechnol. 2001 Apr;3(2):215-8. PubMed PMID: 11321576. 560 561 Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev 36. 562 Microbiol. 2006 Aug;4(8):629-36. PubMed PMID: 16845433. Lacroix FJ, Cloeckaert A, Grepinet O, Pinault C, Popoff MY, Waxin H, et al. Salmonella 563 37. 564 typhimurium acrB-like gene: identification and role in resistance to biliary salts and detergents 565 and in murine infection. FEMS Microbiol Lett. 1996 Jan 15;135(2-3):161-7. PubMed PMID: 566 8595853. 567 Bhattacharyya R, Das K, Sen S, Roy S, Majumder HK. Development of a genus specific 38. primer set for detection of Leishmania parasites by polymerase chain reaction. FEMS Microbiol 568 569 Lett. 1996 Jan 15;135(2-3):195-200. PubMed PMID: 8595858. 570 Zhang X, Bierschenk D, Top J, Anastasiou I, Bonten MJ, Willems RJ, et al. Functional 39. 571 genomic analysis of bile salt resistance in *Enterococcus faecium*. BMC Genomics. 2013 May 572 3;14:299. PubMed PMID: 23641968. Pubmed Central PMCID: PMC3653699. Epub 20130503. Reen FJ, Flynn S, Woods DF, Dunphy N, Chroinin MN, Mullane D, et al. Bile signalling 573 40. 574 promotes chronic respiratory infections and antibiotic tolerance. Sci Rep. 2016 Jul 19;6:29768. 575 PubMed PMID: 27432520. Pubmed Central PMCID: PMC4949476. Epub 20160719. 576 Flynn S, Reen FJ, O'Gara F. Exposure to Bile Leads to the Emergence of Adaptive 41. 577 Signaling Variants in the Opportunistic Pathogen Pseudomonas aeruginosa. Front Microbiol. 2019;10:2013. PubMed PMID: 31555243. Pubmed Central PMCID: PMC6727882. Epub 578 579 20190829. Behroozian S, Sampedro I, Dhodary B, Her S, Yu Q, Stanton BA, et al. *Pseudomonas* 580 42. 581 aeruginosa PAO1 Is Attracted to Bovine Bile in a Novel, Cystic Fibrosis-Derived Bronchial 582 Epithelial Cell Model. Microorganisms. 2022 Mar 26;10(4). PubMed PMID: 35456767. Pubmed Central PMCID: PMC9032244. Epub 20220326. 583 Vos R, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Verleden GM. Transient 584 43. 585 airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant. 2007 May;7(5):1278-87. PubMed PMID: 17456203. 586 Vos R, Blondeau K, Vanaudenaerde BM, Mertens V, Van Raemdonck DE, Sifrim D, et 587 44. 588 al. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather flock together? J Heart Lung Transplant. 2008 Aug;27(8):843-9. PubMed PMID: 18656796. 589

45. Reen FJ, Woods DF, Mooij MJ, Adams C, O'Gara F. Respiratory pathogens adopt a

chronic lifestyle in response to bile. PLoS One. 2012;7(9):e45978. PubMed PMID: 23049911.
 Pubmed Central PMCID: PMC3458808. Epub 20120926.

46. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-51. PubMed PMID: 7722560.

595 47. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. ed. USA: 596 Clinical and Laboratory Standards Institute; 2021.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002
guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis.
2002 Mar 15;34(6):730-51. PubMed PMID: 11850858. Epub 20020213.

- 49. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international
 expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect.
 2012 Mar;18(3):268-81. PubMed PMID: 21793988. Epub 20110727.
- Wang Y, Li J, Zachariah P, Abrams J, Freedberg DE. Relationship between remote
 cholecystectomy and incident *Clostridioides difficile* infection. Clin Microbiol Infect. 2019
 Aug;25(8):994-9. PubMed PMID: 30583059. Pubmed Central PMCID: PMC6589130. Epub
 20181222.
- 51. Franko J, Ferrel B, Pierson P, Raman S, Frankova D, Rearigh LM, et al. Influence of prior appendectomy and cholecystectomy on *Clostridioides difficile* infection recurrence and mortality. Am J Surg. 2020 Jul;220(1):203-7. PubMed PMID: 31668774. Epub 20191023.
- Kwon W, Jang JY, Kim EC, Park JW, Han IW, Kang MJ, et al. Changing trend in bile
 microbiology and antibiotic susceptibilities: over 12 years of experience. Infection. 2013
- 613 Feb;41(1):93-102. PubMed PMID: 23180506. Epub 20121121.
- 53. Wulkersdorfer B, Jaros D, Eberl S, Poschner S, Jager W, Cosentini E, et al. Human Bile
- 615 Reduces Antimicrobial Activity of Selected Antibiotics against *Enterococcus faecalis* and
- 616 *Escherichia coli* In Vitro. Antimicrob Agents Chemother. 2017 Aug;61(8). PubMed PMID:

617 28559254. Pubmed Central PMCID: PMC5527593. Epub 20170725.

- 54. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilatorassociated bacterial pneumonia. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7. PubMed PMID:
 20597676.
- 55. Mehrad B, Clark NM, Zhanel GG, Lynch JP, 3rd. Antimicrobial resistance in hospitalacquired gram-negative bacterial infections. Chest. 2015 May;147(5):1413-21. PubMed PMID:
 25940252. Pubmed Central PMCID: PMC4420185.
- 56. Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of intra-
- abdominal infections: literature's guidelines. World J Gastroenterol. 2012 Mar 7;18(9):865-71.
 PubMed PMID: 22408344. Pubmed Central PMCID: PMC3297044.
- 627 57. Suna N, Yildiz H, Yuksel M, Parlak E, Disibeyaz S, Odemis B, et al. The change in
- microorganisms reproducing in bile and blood culture and antibiotic susceptibility over the years.
 Turk J Gastroenterol. 2014 Jun;25(3):284-90. PubMed PMID: 25141317.
- 530 58. Alves KR, Goulart AC, Ladeira RM, Oliveira IR, Bensenor IM. Frequency of
- 631 cholecystectomy and associated sociodemographic and clinical risk factors in the ELSA-Brasil
- 632 study. Sao Paulo Med J. 2016 May-Jun;134(3):240-50. PubMed PMID: 27355799. Pubmed
- 633 Central PMCID: PMC10496596. Epub 2016/06/30.
- 634 59. Ohara T, Itoh K. Significance of *Pseudomonas aeruginosa* colonization of the
- 635 gastrointestinal tract. Intern Med. 2003 Nov;42(11):1072-6. PubMed PMID: 14686744.
- 636